In Silico Studies Comparing the Adjuvant Therapies Approved for Parkinson’s disease
Abstract
One of the most common neurodegenerative disorders is Parkinson's disease. The occurrence of Parkinson's disease includes loss of dopaminergic function and loss of motor function. It is characterized by non- motor as well as motor features. The medicine sector has been primarily focusing on developing adjunctive therapy for the treatment of Parkinson's disease in order to improve the efficacy of the drugs and to improve the quality of treatment. This study aims in silico screening of the drugs available for adjunctive therapy of Parkinson’s disease. The pharmacokinetic parameters, potential adverse effects, toxicity studies, biological activity and the structure activity relationships of the drugs were analyzed and summarized. The drugs chosen as adjunctive therapy in the treatment of Parkinson's disease have reported high chances of adverse drug events and require precautions before administration. Although, they are therapeutically effective it is necessary to investigate other available therapies and then conclude their efficacy.
Keywords: Adjunct therapy, in silico, Parkinson’s disease, pharmacokinetic study, toxicity profile.
Keywords:
Adjunct therapy, in silico, Parkinson’s disease, pharmacokinetic study, toxicity profileDOI
https://doi.org/10.22270/jddt.v11i3-S.4813References
DeMaagd G, Philip A, "Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis" P T, 2015; 40(8):504-32.
Parkinson's Disease. Parkinson's News Today; 2021 [cited 18 May 2021]. Available at: https://parkinsonsnewstoday.com/parkinsons-disease-treatments/. Accessed May 18, 2021.
Stocchi F, Torti M, "Adjuvant Therapies For Parkinson's Disease: Critical Evaluation of Safinamide" Drug Des Devel Ther, 2016; 10:609-618 https://doi.org/10.2147/DDDT.S77749
Que D-LS, Jamora RDG, "Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review" Clin. Ther, 2021; 43(1):e19-e31. https://doi.org/10.1016/j.clinthera.2020.11.009
Newly Approved Parkinson's Drug Aims to Lessen "Off" Time. The Michael J. Fox Foundation for Parkinson's Research. Parkinson's Disease; 2021. Available at: https://www.michaeljfox.org/news/newly-approved-parkinsons-drug-aims-lessen-time. Accessed May18, 2021
Gelfin E, Kaufman Y, Korn-Lubetzki I, Bloch B, Kremer I, Javitt DC, et al, "D-Serine Adjuvant Treatment Alleviates Behavioural and Motor Symptoms in Parkinson's Disease" Int J Neuropsychopharmacol, 2012; 15(4):543-9.
https://doi.org/10.1017/S1461145711001015
Torti M, Vacca L, Stocchi F, "Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?" Expert Opin Pharmacother, 2018; 19(16):1821-1828 https://doi.org/10.1080/14656566.2018.1524876
Approved Medications, American Parkinson Disease Assoc. APDA; 2021. Available at: https://www.apdaparkinson.org/what-is-parkinsons/treatment-medication/medication/. Accessed May 18, 2021.
Dhage MS, Nila G, Dhivya D, Sarvesh S, "In Silico Prediction and Pharmacokinetic Comparison of Ursodeoxycholic Acid and Obeticholic Acid in the Management of Primary Biliary Cholangitis" J. drug deliv. Ther, 2021; 11(2):113-117. https://doi.org/10.22270/jddt.v11i2-S.4669
Sarvesh S, Sathish kumar RC, Vijayakumar TM, "CYP3A4 Mediated Pharmacokinetic Drug interaction potential of Maha-Yogaraj Gugglu and E,Z Guggulsterone" Nature Res, 2021; 11(1):715. https://doi.org/10.1038/s41598-020-80595-5
Sarvesh S, Haripritha M, Preethi L, Arjun Gokulan M, Dhivya D, Nila G, Rahul R, "HCIP: an online database for prediction CYP450 Enzyme Inhibition Potential of Bioactive Compounds" J. drug deliv. Ther, 2021; 11(2). https://doi.org/10.22270/jddt.v11i2.4637
Sarvesh S, Vijayakumar TM, "Isomers of Guggulsterone in hyperlipidemia" Obs Med, 2021; 22(7,72):100326. https://doi.org/10.1016/j.obmed.2021.100326
Gadaleta D, Vuković K, Toma C, Lavado GJ, Karmaus AL, Mansouri K, et al, "SAR and QSAR modeling of a large collection of LD50 rat acute oral toxicity data" J. Cheminformatics, 2019; 11(1):58. https://doi.org/10.1186/s13321-019-0383-2
Preethi L, Nila G, Dhivya D, Sarvesh S, "Therapeutic use of Guggulsterone in COVID-19 induced obesity (COVIBESITY) and significant role in immunomodulatory effect" ObesMed, 2021; 24:100346. https://doi.org/10.1016/j.obmed.2021.100346
Banerjee P, Eckert AO, Schrey AK, Preissner R, "ProTox-II: a Webserver for the Prediction of Toxicity of Chemicals" Nucleic Acids Res, 2018; 46(W1):W257-W63. https://doi.org/10.1093/nar/gky318
Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, et al, "Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource" Chem Heterocycl Comp,2014; 50(3):444-57. https://doi.org/10.1007/s10593-014-1496-1
Filimonov DA, Rudik AV, Dmitriev AV, Poroikov VV, "Computer-Aided Estimation of Biological Activity Profiles of Drug-Like Compounds Taking into Account Their Metabolism in Human Body" Int. J. Mol. Sci, 2020; 21(20):7492. https://doi.org/10.3390/ijms21207492
Ertl P, Rohde B, Selzer P, "Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and its Application to the Prediction of Drug Transport Properties" J. Med. Chem, 2000; 43(20):3714-3717. https://doi.org/10.1021/jm000942e
Ayati A, Falahati M, Irannejad H, Emami S,"Synthesis, In vitro Antifungal Evaluation and In silico Study of 3-azolyl-4-chromanone phenylhydrazones" Daru, 2012; 20(1):46. https://doi.org/10.1186/2008-2231-20-46
Mannens GSJ, Bohets H, Verboven P, Steemans K, Lavrijsen K, Meuldermans W. Rapid Permeability Screening in Drug Discovery to Predict Human Intestinal Absorption. In: Pelkonen O., Baumann A., Reichel A. (eds) Pharmacokinetic Challenges in Drug Discovery. Ernst Schering Research Foundation Workshop, vol 37. Springer, Berlin, Heidelberg: 2002.p. 49-67. https://doi.org/10.1007/978-3-662-04383-7_3
van Breemen RB, Li Y, "Caco-2 Cell Permeability Assays to Measure Drug Absorption" Expert Opin Drug Metab Toxicol, 2005; 1(2):175-85 https://doi.org/10.1517/17425255.1.2.175
Xiong S, Li Z, Liu Y, Wang Q, Luo J, Chen X, et al, "Brain-targeted Delivery Shuttled by Black Phosphorus Nanostructure to Treat Parkinson's Disease" Biomaterials, 2020; 260:120339. https://doi.org/10.1016/j.biomaterials.2020.120339
Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H,"Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by using various Cheminformatics Approaches" Pharm Res, 2014; 31(4):1002-14. https://doi.org/10.1007/s11095-013-1222-1
Guardia-Laguarta C, Area-Gomez E, Schon EA, Przedborski S, "Novel Subcellular Localization for α-synuclein: Possible Functional Consequences" Front Neuroanat, 2015; 23(9):17. https://doi.org/10.3389/fnana.2015.00017
Stefanis L, "α-Synuclein in Parkinson's disease" Cold Spring Harb Perspect Med, 2012; 2(2):a009399. https://doi.org/10.1101/cshperspect.a009399
Savjani KT, Gajjar AK, Savjani JK, "Drug Solubility: Importance and Enhancement Techniques" ISRN Pharm, 2012; 2012:195727. https://doi.org/10.5402/2012/195727
Sorkun MC, Khetan A, Er S, "AqSolDB, a Curated Reference Set of Aqueous Solubility and 2D Descriptors for a Diverse Set of Compounds" Sci Data, 2019; 6: 143. https://doi.org/10.1038/s41597-019-0151-1
Trainor GL, "The Importance of Plasma Protein Binding in Drug Discovery" Expert Opin Drug Discov, 2007; 2(1):51-64. https://doi.org/10.1517/17460441.2.1.51
Sommer S, Buraczewska I, Kruszewski M, "Micronucleus Assay: The State of Art, and Future Directions" Int J Mol Sci, 2020; 24;21(4):1534. https://doi.org/10.3390/ijms21041534
Caco-2 cells Permeability Assay Protocol - In vitro Intestinal Absorption Evaluation. ReadyCell In vitro Tools; 2021. Available at: https://readycell.com/caco-2-permeability-protocol/. Accessed May 18, 2021.
Damião M, Pasqualoto K, Polli M, Parise Filho R, "To Be Drug or Prodrug: Structure-Property Exploratory Approach Regarding Oral Bioavailability" J. Pharm. Pharm. Sci, 2014; 17:532-40. https://doi.org/10.18433/J3BS4H
Banerjee P, Eckert AO, Schrey AK, Preissner R, "ProTox-II: a webserver for the prediction of toxicity of chemicals" Nucleic Acids Res, 2018; 29, 46(W1):W257-W263. https://doi.org/10.1093/nar/gky318
Erhirhie EO, Ihekwereme CP, Ilodigwe EE, "Advances in Acute Toxicity Testing: Strengths, Weaknesses and Regulatory Acceptance" Interdiscip Toxicol, 2018; 11(1):5-12. https://doi.org/10.2478/intox-2018-0001
Lipinski CA, "Lead- and drug-like compounds: the rule-of-five revolution" Drug Discovery Today: Technologies, 2004; 1(4):337-41. https://doi.org/10.1016/j.ddtec.2004.11.007
Khan T, Dixit S, Ahmad R, Raza S, Azad I, Joshi S, Khan AR, "Molecular Docking, PASS Analysis, Bioactivity Score Prediction, Synthesis, Characterization and Biological Activity Evaluation of a Functionalized 2-butanone thiosemicarbazone Ligand and its Complexes" J Chem Biol. 2017; 10(3):91-104. https://doi.org/10.1007/s12154-017-0167-y
Husain A, Ahmad A, Khan S, Asif M, Bhutani R, Al-Abbasi F, "Synthesis, molecular properties, toxicity and biological evaluation of some new substituted Imidazolidine derivatives in search of potent Anti-inflammatory agents" Saudi Pharm J, 2015; 43. https://doi.org/10.1016/j.jsps.2015.02.008
Published
Abstract Display: 570 
PDF Downloads: 719 PDF Downloads: 112 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.